Morepen Laboratories shares touched a 52-week high of ₹135.35 after submitting its first-ever drug application for Sitagliptin tablets to the US FDA. This move signals a strategic shift toward high-value finished medicines. Investors are now tracking the company's entry into the competitive US market, balanced against its rising debt levels and high stock valuation.
Morepen Laboratories stock reached a 52-week high of ₹135.35 on October 1, 2026, following the company's announcement that it has submitted its first-ever Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration (FDA). This formal application, filed on September 25, 2026, is for Sitagliptin tablets, a medicine widely used for managing type 2 diabetes. The stock price movement reflects strong investor interest in the company's transition from a basic chemical ingredient manufacturer to a supplier of finished medicines.
Strategic Business Shift
For years, Morepen Laboratories primarily focused on producing Active Pharmaceutical Ingredients (APIs), which are the raw materials used to make medicines. This new filing represents a pivot toward the integrated CDMO (Contract Development and Manufacturing Organization) model. By developing and filing for finished dosage forms, the company aims to move up the value chain. Management has indicated that commercial supply could take 24 to 36 months, as the timeline depends on regulatory reviews, potential facility inspections, and navigating existing patent rights for the drug.
Financial Performance and Momentum
The stock's recent performance is supported by a strong set of numbers in its latest quarterly report. For the first quarter of the 2027 fiscal year, the company reported a standalone and consolidated revenue of ₹575.31 crore, a growth of 34% compared to the previous year. Net profit also saw a sharp increase, rising 394% to ₹56.35 crore. This growth has helped build investor confidence, though the stock is currently trading at a relatively high valuation with a price-to-earnings (P/E) ratio of approximately 46.87.
Risks and Monitorables
While the expansion into the US market is a growth catalyst, investors should consider several risks. First, filing an application does not guarantee approval. The US FDA has a rigorous review process, and any delays or queries can push back commercial timelines. Furthermore, the market for generic Sitagliptin is highly competitive, which may pressure profit margins once the product is eventually launched.
On the balance sheet side, debt management is an area to watch. The company's debt level rose to ₹195 crore as of March 2026, up from ₹79 crore in March 2025. While this increase is linked to the company's capital spending and expansion efforts, higher borrowing costs can impact cash flow if revenue growth does not keep pace. Moving forward, the most important updates for shareholders will be the US FDA’s feedback on this application, the company's ability to maintain its profit margins amid competition, and the management of its debt obligations.